RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RegeneRx Biopharmaceuticals Stock

RegeneRx Biopharmaceuticals Stocks 2024

RegeneRx Biopharmaceuticals Stocks

1.44 M

Ticker

RGRX

ISIN

US75886X1081

WKN

875295

In 2024, RegeneRx Biopharmaceuticals had 1.44 M outstanding stocks, a 3.58% change from the 1.39 M stocks in the previous year.

The RegeneRx Biopharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
20221.44
20211.39
20201.33
2019130.97
2018120.72
2017120.93
2016125.92
2015101.53
201493.19

RegeneRx Biopharmaceuticals shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RegeneRx Biopharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RegeneRx Biopharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RegeneRx Biopharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RegeneRx Biopharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

RegeneRx Biopharmaceuticals Aktienanalyse

What does RegeneRx Biopharmaceuticals do?

RegeneRx Biopharmaceuticals Inc is a biotechnology company focused on the development and commercialization of drugs for the treatment of diseases. The company is headquartered in Rockville, Maryland and was founded in 1982. Since its inception, RegeneRx has brought various products to market and is known for its research in tissue regeneration. The company started its early years with research in the field of nerve regeneration. As a result of this research, RegeneRx developed its first chemical called Thymosin beta 4 (Tβ4). Tβ4 is a naturally occurring protein produced in the human body. It serves as a growth factor for cells and plays an important role in healing damaged tissue. RegeneRx used this knowledge and began intensive work on the growth of Tβ4 in the laboratory. The company's researchers soon realized that Tβ4 was not only important for nerve regeneration, but could also be used in skin damage, stroke, and heart attack treatment. The researchers continued to work on the substance and in 1999 successfully brought the so-called Eye Drop product A3G12 to the market. This product is used to treat eye injuries and infections. In the following years, RegeneRx continued to research Tβ4. It was found that Tβ4 could also be successfully used in COPD (Chronic Lung Problems), wound healing, and bone disorders. Various products were developed for this purpose, available under the names RGN-137, RGN-259, and RGN-352. RegeneRx has also formed partnerships with other pharmaceutical companies such as Axio Biosolutions and Gtree BNP, and has successfully collaborated with them. In early 2021, it was decided that RegeneRx would expand its expertise in the Asian market and signed an agreement with Gtree BNP. The two companies planned to market RegeneRx products RGN-503 and RGN-352 in South Korea. Overall, RegeneRx Biopharmaceuticals Inc. has developed an impressive list of products that have successfully undergone patent and regulatory processes. These products treat a variety of diseases and injuries. RegeneRx is committed to continuing its research in this field and developing new products to help improve the health and well-being of patients worldwide. The company's business model primarily focuses on research and development. It has expanded in recent years due to the high potential of Tβ4 and its use in many medical areas. RegeneRx expects that by expanding the use of Tβ4, there will be greater acceptance and demand for its products worldwide. RegeneRx Biopharmaceuticals Inc is a company operating in the field of regenerative medicine. The products are typically positioned in the higher price range, in line with the company's market positioning. The company has successfully collaborated with other pharmaceutical companies in the past and is expected to form further alliances. RegeneRx sees itself as a leading biotechnology company focused on innovative drugs. RegeneRx Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating RegeneRx Biopharmaceuticals's Shares Outstanding

RegeneRx Biopharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in RegeneRx Biopharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding RegeneRx Biopharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in RegeneRx Biopharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about RegeneRx Biopharmaceuticals stock

How many stocks are there of RegeneRx Biopharmaceuticals?

The current number of stocks of RegeneRx Biopharmaceuticals is 1.44 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of RegeneRx Biopharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of RegeneRx Biopharmaceuticals evolved in recent years?

The number of shares of RegeneRx Biopharmaceuticals has increased by 3.58% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. RegeneRx Biopharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of RegeneRx Biopharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does RegeneRx Biopharmaceuticals pay?

Over the past 12 months, RegeneRx Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RegeneRx Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of RegeneRx Biopharmaceuticals?

The current dividend yield of RegeneRx Biopharmaceuticals is .

When does RegeneRx Biopharmaceuticals pay dividends?

RegeneRx Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of RegeneRx Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RegeneRx Biopharmaceuticals located?

RegeneRx Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von RegeneRx Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RegeneRx Biopharmaceuticals from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did RegeneRx Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of RegeneRx Biopharmaceuticals in the year 2023?

In the year 2023, RegeneRx Biopharmaceuticals distributed 0 USD as dividends.

In which currency does RegeneRx Biopharmaceuticals pay out the dividend?

The dividends of RegeneRx Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von RegeneRx Biopharmaceuticals

Our stock analysis for RegeneRx Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RegeneRx Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.